Alcon/$ALC

1D1W1MYTD1Y5YMAX

About Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Health
Primary listing
NYSE
Employees
25,000
Headquarters
Geneva, Switzerland
Website
www.alcon.com

Alcon Metrics

BasicAdvanced
$32B
49.56
$1.31
0.70
$0.23
0.36%

What the Analysts think about Alcon

Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Analyst projections of the future price of Alcon stock.

Bulls say / Bears say

Alcon’s second-quarter sales rose 8% reported and 7% constant currency, while core diluted EPS increased 11%; management raised its 2026 core operating-margin and core EPS-growth outlook. (Alcon/SEC)
Recent launches—including UNITY, PanOptix Pro, TRYPTYR, and Precision7—are driving growth, with management reporting continued contact-lens share gains and a robust pipeline of additional launches. (Alcon/SEC)
Cash generation supports shareholder returns: first-half free cash flow reached $693 million, and Alcon returned $538 million through dividends and repurchases while retaining approximately $1.2 billion under its $1.5 billion buyback authorization. (Alcon/SEC)
Tariffs remain a material margin risk: Alcon expects a net full-year 2026 impact of approximately $40 million–$90 million, assuming U.S. import tariffs of roughly 10%–12.5% remain in effect through year-end. (Alcon/SEC)
Reported earnings quality is weaker than core results suggest: second-quarter diluted EPS was $0.00, while first-half diluted EPS fell 63%, primarily because of a $287 million post-tax, non-cash charge tied to discontinued PowerVision programs and efficiency costs. (Alcon/SEC)
Alcon added refinancing and interest-rate exposure by pricing €500 million of 3.875% senior notes due 2033 for general corporate purposes, including potentially refinancing existing debt. (Alcon)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.

Alcon Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Alcon Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Alcon News

AllArticlesVideos

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Business Wire2 weeks ago

Alcon Prices EUR 500 Million Senior Notes Offering

Business Wire4 weeks ago

Eye care company Alcon raises profitability outlook, cuts tariff hit estimate

Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.